Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: An exploratory study comparing two consensus-based frameworks

Barbara S van der Meij, Coline P Schoonbeek, Egbert F Smit, Maurizio Muscaritoli, Paul A M van Leeuwen, Jacqueline A E Langius

Research output: Contribution to journalArticleResearchpeer-review

28 Citations (Scopus)

Abstract

Despite the development of consensus-based frameworks to define cancer cachexia, the validity and usefulness of these frameworks are relatively unknown. The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III nonsmall-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. In forty patients at diagnosis of stage III NSCLC, weight loss, fat-free mass, handgrip strength, anorexia and serum biochemistry, assessed before the first chemotherapy, were used to define ‘cancer cachexia’ or ‘cachexia’. The cancer-specific framework also classified for pre-cachexia and refractory cachexia. Additionally, quality of life was assessed by the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire C30. Groups were compared using independent t tests, ANOVA, Kaplan–Meier and Cox survival analyses. Based on the cancer-specific framework, pre-cachexia was present in nine patients (23%) and cancer cachexia was present in seven patients (18%). Cancer cachexia was associated with a reduced quality of life (P = 0.03) and shorter survival (hazard ratio (HR) = 2.9; P = 0.04). When using the general framework, cachexia was present in eleven patients (28%), and was associated with a reduced quality of life (P = 0.08) and shorter survival (HR = 4.4; P = 0.001). In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. For both frameworks, cachexia appears to be associated with a reduced quality of life and shorter survival. Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients.

Original languageEnglish
Pages (from-to)2231-9
Number of pages9
JournalBritish Journal of Nutrition
Volume109
Issue number12
DOIs
Publication statusPublished - 28 Jun 2013
Externally publishedYes

Fingerprint

Cachexia
Non-Small Cell Lung Carcinoma
Consensus
Neoplasms
Quality of Life
Carcinoma
Lung
Survival
Anorexia

Cite this

van der Meij, Barbara S ; Schoonbeek, Coline P ; Smit, Egbert F ; Muscaritoli, Maurizio ; van Leeuwen, Paul A M ; Langius, Jacqueline A E. / Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma : An exploratory study comparing two consensus-based frameworks. In: British Journal of Nutrition. 2013 ; Vol. 109, No. 12. pp. 2231-9.
@article{51204339fc8a4622a0c30d8419ec2439,
title = "Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma: An exploratory study comparing two consensus-based frameworks",
abstract = "Despite the development of consensus-based frameworks to define cancer cachexia, the validity and usefulness of these frameworks are relatively unknown. The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III nonsmall-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. In forty patients at diagnosis of stage III NSCLC, weight loss, fat-free mass, handgrip strength, anorexia and serum biochemistry, assessed before the first chemotherapy, were used to define ‘cancer cachexia’ or ‘cachexia’. The cancer-specific framework also classified for pre-cachexia and refractory cachexia. Additionally, quality of life was assessed by the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire C30. Groups were compared using independent t tests, ANOVA, Kaplan–Meier and Cox survival analyses. Based on the cancer-specific framework, pre-cachexia was present in nine patients (23{\%}) and cancer cachexia was present in seven patients (18{\%}). Cancer cachexia was associated with a reduced quality of life (P = 0.03) and shorter survival (hazard ratio (HR) = 2.9; P = 0.04). When using the general framework, cachexia was present in eleven patients (28{\%}), and was associated with a reduced quality of life (P = 0.08) and shorter survival (HR = 4.4; P = 0.001). In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. For both frameworks, cachexia appears to be associated with a reduced quality of life and shorter survival. Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients.",
author = "{van der Meij}, {Barbara S} and Schoonbeek, {Coline P} and Smit, {Egbert F} and Maurizio Muscaritoli and {van Leeuwen}, {Paul A M} and Langius, {Jacqueline A E}",
year = "2013",
month = "6",
day = "28",
doi = "10.1017/S0007114512004527",
language = "English",
volume = "109",
pages = "2231--9",
journal = "British Journal of Nutrition",
issn = "0007-1145",
publisher = "Cambridge University Press",
number = "12",

}

Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma : An exploratory study comparing two consensus-based frameworks. / van der Meij, Barbara S; Schoonbeek, Coline P; Smit, Egbert F; Muscaritoli, Maurizio; van Leeuwen, Paul A M; Langius, Jacqueline A E.

In: British Journal of Nutrition, Vol. 109, No. 12, 28.06.2013, p. 2231-9.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Pre-cachexia and cachexia at diagnosis of stage III non-small-cell lung carcinoma

T2 - An exploratory study comparing two consensus-based frameworks

AU - van der Meij, Barbara S

AU - Schoonbeek, Coline P

AU - Smit, Egbert F

AU - Muscaritoli, Maurizio

AU - van Leeuwen, Paul A M

AU - Langius, Jacqueline A E

PY - 2013/6/28

Y1 - 2013/6/28

N2 - Despite the development of consensus-based frameworks to define cancer cachexia, the validity and usefulness of these frameworks are relatively unknown. The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III nonsmall-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. In forty patients at diagnosis of stage III NSCLC, weight loss, fat-free mass, handgrip strength, anorexia and serum biochemistry, assessed before the first chemotherapy, were used to define ‘cancer cachexia’ or ‘cachexia’. The cancer-specific framework also classified for pre-cachexia and refractory cachexia. Additionally, quality of life was assessed by the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire C30. Groups were compared using independent t tests, ANOVA, Kaplan–Meier and Cox survival analyses. Based on the cancer-specific framework, pre-cachexia was present in nine patients (23%) and cancer cachexia was present in seven patients (18%). Cancer cachexia was associated with a reduced quality of life (P = 0.03) and shorter survival (hazard ratio (HR) = 2.9; P = 0.04). When using the general framework, cachexia was present in eleven patients (28%), and was associated with a reduced quality of life (P = 0.08) and shorter survival (HR = 4.4; P = 0.001). In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. For both frameworks, cachexia appears to be associated with a reduced quality of life and shorter survival. Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients.

AB - Despite the development of consensus-based frameworks to define cancer cachexia, the validity and usefulness of these frameworks are relatively unknown. The aim of the present study was to study the presence of pre-cachexia and cachexia in patients with stage III nonsmall-cell lung carcinoma (NSCLC) by using a cancer-specific framework and a general framework for cachexia, and to explore the prognostic value of pre-cachexia and cachexia. In forty patients at diagnosis of stage III NSCLC, weight loss, fat-free mass, handgrip strength, anorexia and serum biochemistry, assessed before the first chemotherapy, were used to define ‘cancer cachexia’ or ‘cachexia’. The cancer-specific framework also classified for pre-cachexia and refractory cachexia. Additionally, quality of life was assessed by the European Organisation for Research and Treatment of Cancer–Quality of Life Questionnaire C30. Groups were compared using independent t tests, ANOVA, Kaplan–Meier and Cox survival analyses. Based on the cancer-specific framework, pre-cachexia was present in nine patients (23%) and cancer cachexia was present in seven patients (18%). Cancer cachexia was associated with a reduced quality of life (P = 0.03) and shorter survival (hazard ratio (HR) = 2.9; P = 0.04). When using the general framework, cachexia was present in eleven patients (28%), and was associated with a reduced quality of life (P = 0.08) and shorter survival (HR = 4.4; P = 0.001). In conclusion, pre-cachexia and cachexia are prevalent in this small population of patients at diagnosis of stage III NSCLC. For both frameworks, cachexia appears to be associated with a reduced quality of life and shorter survival. Further studies are warranted to more extensively explore the validity and prognostic value of these new frameworks in cancer patients.

U2 - 10.1017/S0007114512004527

DO - 10.1017/S0007114512004527

M3 - Article

VL - 109

SP - 2231

EP - 2239

JO - British Journal of Nutrition

JF - British Journal of Nutrition

SN - 0007-1145

IS - 12

ER -